Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00370747 | Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome | PHASE2 | COMPLETED | 162 | — | — | Sep 1, 2006 | Jun 1, 2007 | Mar 15, 2013 | 1 | United States |
ocular signs, including corneal and conjunctival staining, tear film breakup time and blink rate, and ocular symptoms, including burning or stinging, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, photophobia, photopsia, and eye discomfort
| Arm | Type | Description |
|---|---|---|
| Ecabet | EXPERIMENTAL | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Placebo | PLACEBO_COMPARATOR | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Name | Type | Description |
|---|---|---|
| Ecabet | DRUG | ophthalmic solution 2.83% |
| Placebo | DRUG | - |
Inclusion Criteria: * Male/female at least 18 years of age * Agree to avoid disallowed medications * Have a diagnosis of dry eye Exclusion Criteria: * Have chronic systemic inflammation * Have active seasonal ocular allergies